Abstracts tagged "Connective tissue diseases and pulmonary complications"

Abstract Number: 1314 • 2018 ACR/ARHP Annual Meeting
Autoantibodies and Clinical Outcomes in Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases
Yuko Shirota¹, Tomonori Ishii², Tsuyoshi Shirai¹, Hiroshi Fujii¹ and Hideo Harigae¹, ¹Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ²Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan
Background/Purpose: Pulmonary arterial hypertension (PAH) associated with SSc (SSc-PAH) has a substantially worse prognosis as compared to other connective tissue diseases (CTD)-PAH. Although SSc-PAH are…
Abstract Number: 621 • 2013 ACR/ARHP Annual Meeting
Baseline Characteristics That Predict a Short-Term Response To Immunosuppressive Treatment In Patients With Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
Hidekata Yasuoka¹, Yuichiro Shirai¹, Yuichi Tamura², Toru Satoh³, Tsutomu Takeuchi¹ and Masataka Kuwana¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Department of Cardiology, Keio University School of Medicine, Tokyo, Japan, ³Department of Cardiology, Kyorin University School of Medicine, Tokyo, Japan
Background/Purpose: Pulmonary arterial hypertension (PAH) is one of devastating organ involvements in patients with connective tissue diseases (CTDs). Recent introduction of molecular-targeting PAH drugs, such…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].